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Summary Natural human interferon f, (fi-IFN) was tested during the early phase of in vitro infection with
HTLV-I virus of human cord blood mononuclear cells (CBL), to evaluate whether its antiviral and
immunomodulating effects might prevent spreading of infection in the host. ,B-IFN was found to reduce
HTLV-I transmission and integration in CBL cultures. Moreover, ,B-IFN had no effect in preventing virus
transmission and integration in K562 and a very limited effect in HL60 and Molt-4 human tumour lines,
suggesting a cell-type specific mode of action.
/3-IFN induced a 'priming' response on CBL, since overnight pretreatment of recipient cells or one single
treatment at the onset of the coculture were almost equally effective in protecting against HTLV-I infection.
During the early days post infection (p.i.), IFN-treated CBL showed a pattern of phenotypic markers that
was closer to that of non-infected CBL. In contrast, untreated CBL exposed to HTLV-I showed a percent
increase of Tac +, M3 + and Leu 11+ subpopulations.
Cell-mediated immune responses of CBL were depressed after coculturing with HTLV-I producer MT-2
cells. fl-IFN was able to boost the cell-mediated cytotoxicity of fresh and infected CBL against both K562
and MT-2 target cells. Leukocyte blastogenesis in mixed lymphocyte/tumour cell cultures, evaluated in terms
of 3H-thymidine incorporation during the first week p.i., was also enhanced by IFN when macrophages and
lymphocytes were reconstituted at an optimal 1:20 ratio. It is conceivable that this overall enhancement of the
immune response induced by ,B-IFN could contribute to reduce HTLV-I infection in vitro.
Human T-cell leukaemia/lymphoma virus type I (HTLV-I),
was the first human retrovirus to be associated with an
aggressive form of adult T-cell leukaemia (ATL) (Gallo,
1985; Takatsuki et al., 1985). HTLV-I is highly tropic for the
CD4+ lymphocyte subset and integrates in the genome
leading to transformation. The surface phenotype of ATL
cells, as characterised by monoclonal antibodies, is CD3+,
CD4+, CD8-, CD11- (Hattori et al., 1981). ATL cells
also express IL-2 receptors and class II HLA antigens
(Waldmann et al., 1984). However, HTLV-I transmission
does not seem to be restricted to T lymphocytes, since B-cells
(Longo et al., 1984; Tomita et al., 1985), some non-lymphoid
cell lines (Clapham et al., 1983) and primary endothelial cell
cultures (Ho et al., 1984; Hoxie et al., 1984) can also be
infected in vitro. Receptors for HTLV-I are indeed present
on different types of cells from various species, although not
all the receptor-positive cells are susceptible to stable
infection (Sinangil et al., 1985). The mechanisms of tissue-
specific transformation mediated by HTLV-I are still
unclear. It has been suggested that they are mediated by
trans-acting transcriptional factor(s) of viral origin, that
regulate(s) both HTLV promoter/enhancer sequences and
activation of specific cellular genes controlling lymphocyte
growth (Weiss, 1984; Haseltine et al., 1985).
HTLV-I infection is accompanied by several alterations
in immune function, including T-cell proliferation
independently of IL-2 regulation (Popovic et al., 1983a,b)
and indiscriminant helper function (Popovic et al., 1984;
Volkam et al., 1985; Yarchoan et al., 1986). Since the
specific target cell of HTLV-I is an immunocompetent cell,
infection of T lymphocytes would result in a severe
dysfunction of the immune system, which in turn could fail
to control virus infection. Therefore, it is reasonable to
hypothesize that immunosurveillance mechanisms play a
significant role in controlling the early stages of HTLV-I
transmission and preventing spreading of infection. In this
respect, immunomodulating agents influence the rate and
extent of target cell infection. They could protect from a
massive horizontal transmission of HTLV-I and/or prevent
the selection of the transformed clone(s).
Interferons (IFNs) are potent antiviral and antitumour
agents (Lengyel, 1982). oc and f3-IFN have been tested in
clinical trials for therapy of virus-induced diseases (Scott,
1983). The effects of IFNs may be amplified by their known
ability to modulate the immune system by regulating
macrophage and lymphocyte functions. In view of this
possibility, the effects of P-IFN on early stages of in vitro
infection with HTLV-I have been tested. The present results
show that f-IFN could effectively reduce both HTLV-I
transmission and integration in human cord blood
lymphocytes (CBL). This effect appeared to be cell type-
specific and could be due, at least in part, to boosting of the
immune function of recipient CBL.
Materials and methods
Cell cultures and infection
Human mononuclear cells were collected from heparinized
neonatal umbilical cord blood (CBL) on Ficoll-Hypaque
(Pharmacia, Uppsala, Sweden) gradients (1.077 gcm-3)
(B0yum, 1968), seeded in 24-well plates or 25cm2 flasks
(Falcon, Oxnard, USA) at a density of 0.5-1 x 106ml1 and
incubated at 37°C in humidified air containing 5% CO2.
Human tumour lines were grown in 25cm2 flasks (Falcon)
and diluted serially every 2 days. The culture medium was
RPMI 1640 (Gibco, Grand Island, USA), plus 20% heat-
inactivated foetal calf serum (FCS) (Gibco), 2mM
glutamine (Gibco) and 100 Uml- penicillin/streptomycin.
For CBL cultures, the medium was supplemented with 5%
purified IL-2 (Cellular Products, Buffalo, USA) to guarantee
the survival of lymphocytes (Morgan et al., 1976). In long-
term CBL cultures, the medium was renewed every week and
fresh IL-2 added. Infection was achieved by coculturing CBL
or recipient tumour lines with an HTLV-I producer line,
MT-2 (Miyoshi et al., 1981; Yoshida et al., 1982), at a ratio
of 5:1. MT-2 cells were lethally irradiated (120Gy, Cesium
Gamma Cell 1000, Canada Atomic Energy Ltd., Canada)
before co-culturing. The human cell lines used as recipient
cells were the erythroleukaemia K562 (Lozzio & Lozzio,
1975), the lymphoma Molt-4 (Minowada et al., 1982) and
the promyelocytic leukaemia HL-60 (Collins et al., 1977)
lines.
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Interferon treatment
A freeze-dried preparation of natural fl-IFN was kindly
provided by Sclavo, Siena, Italy. It was resuspended in
RPMI 1640 medium and aliquots were stored at -170°C. ,B-
IFN was added to cell cultures at concentrations of 100 and
1000Uml-1. The scheme of treatments was as follows: (a)
pretreatment of recipient cells overnight; (b) pretreatment of
virus donor cells overnight; (c) treatment with f,-IFN at the
onset of the coculture (hereafter referred to as 'cotreatment').
After pretreatment according to scheme (a), recipient CBL
were washed and transferred again in the same wells or
flasks to keep unaltered the originally plated monocyte
population.
Indirect immunofluorescencefor HTLV-I infected cells and
surface phenotype ofCBL
To determine the percentage of HTLV-I infected cells,
- 5 x 105 cells were dispensed to 10 well multitest glass slides
(Flow Laboratories, Irvine, UK), air-dried and fixed for
10min in acetone/methanol (3:1); 10M1 1:400 diluted
monoclonal antibody to HTLV-I p19 core protein (Robert-
Guroff et al., 1981) were added to each spot for 30min.
After washing for, 1 h in PBS plus 0.25% triton X100 (Sigma,
St. Louis, USA), 10p1 1:40 diluted rabbit anti-mouse IgG
(Fab' fragment) coupled with fluorescein-isothiocyanate
(FITC) (Bio-Yeda, Rehovot, Israel) were added for 30min.
Samples were then washed overnight in PBS plus 0.25%
triton X100, air-dried and mounted with glycerol. Percent
positive cells were scored by fluorescence microscopy (Leitz,
Wetzlar, FRG). MT-2 cells, nearly 100% p19+, were taken
as a positive control, and non-infected CBL or tumour cell
lines as a negative control in each experiment.
The surface phenotype of CBL during in vitro infection
with HTLV-I was determined by using monoclonal
antibodies to surface markers. Leu 2a (CD8+), Leu 3a
(CD4+), Leu 7 (LGL), Leu 12 (B lymphocytes) and M3
(monocytes/macrophages) were purchased from Becton-
Dickinson (Sunnyvale, USA). Anti-Tac (IL-2 receptor)
monoclonal antibody was kindly provided by T.A.
Waldmann. Briefly, 106 cells/vial were resuspended in 10,ul
monoclonal antibody and incubated for 30min on ice. After
washing twice with PBS plus 5% FCS, cells were
resuspended in 1:40 diluted rabbit anti mouse FITC-IgG or
IgM (Bio-Yeda) for 30min on ice, washed again, seeded on
10 well-multitest glass slides (Flow) and air-dried. Samples
were then fixed in ethanol/acetic acid (10:1) at -20°C,
rehydrated by washing with cold PBS and mounted with
glycerol and cover slips. Alternatively, the surface phenotype
of CBL was evaluated by the direct immunofluorescence
method (FITC-conjugated monoclonal antibodies, Becton-
Dickinson) on a FACS analyzer (Becton-Dickinson).
DNA extraction, DOT blots and hybridization procedure
Genomic DNA was extracted from CBL or cell line pellets
using the standard proteinase K method and resuspended in
sterile TE buffer (Tris-HCI 1OmM, EDTA 1 mM). The yield
was - 10 ug DNA 10-6 cells. RNA contamination of the
samples was eliminated by digestion with DNAase-free
RNAase. Dot blot analysis was performed according to
Kafatos et al. (1979) as modified by G. Schutz. Briefly,
samples were denatured (0.2M NaOH for 10min at 65'C),
neutralized by adding 1 vol 2M ammonium acetate, and
spotted on nitrocellulose filter (Schleicher & Schill, Dassel,
FRG) previously saturated with 1 M ammonium acetate. Air-
dried filters were baked for 2h at 80°C. pMT-2 plasmid was
kindly given by Dr R.C. Gallo; it contains the SstI-SstI
fragment of HTLV-I (8.5 kb, accounting for almost the
entire provirus sequences) cloned in pSP64. After digestion
with SstI (Gibco/BRL, Eggenstein, FRG), the HTLV-I
fragment was nick-translated by using 32P-dATP and 32P_
dCTP nucleotides (Amersham Int., Amersham, UK). Specific
activity of labelled probes was 1 x 108 cpm g -1 DNA.
Hybridization was performed in 1-5ml of 10xDenhardt's
solution-4 x SET-0.1% SDS (20 x SET=3M NaCl, 0.6M
Tris pH 8, 40mM EDTA), in sealed plastic bags, at 65°C for
20h. After hybridization, the filters were washed for 15min
in 10 x Denhardt's-4 x SET-0.1% SDS, 15min in 2 x SET-
0.1% SDS at 65°C and exposed for 4-12h at -80°C onto
Kodak X AR-5 film (Kodak Company, Rochester, USA).
Assayfor cell mediated cytotoxicity
Natural and antigen-specific cellular cytotoxicity of CBL
were assayed from day 0 up to 4 weeks of coculture by
51Cr-release of labelled target cells (K562 or MT-2) in a 4h
test. Target cells were labelled in 0.1ml FCS plus 100yCi
51Cr-sodium chromate (Amersham) for 1 h at 37°C. Effector
CBL (2 x 105/well) were plated in round bottom 96-well micro-
titer plates. 51Cr-target cells were added at graded
effector/target ratios, from 100:1 to 12.5: 1. After 4h
incubation at 37°C in 5% CO2 humidified air, 0.1ml/well
out of the 0.2ml total supernatant was collected and counted
in a gamma-scintillation counter (Packard, Instrument Co.
Mod. A8000, Downers Grove, USA). Percent specific lysis
was calculated according to the formula (Herberman et al.,
1974):
% specific lysis
cpm sample release-cpm autologous release
total cpm
x 100
Autologous release represents the release of target cells
incubated with non-labelled target cells as effector cells.
Calculation oflytic units
Dose-response curves were obtained by plotting the
percentage of specific 51Cr release and the effector:target
ratios. The best fit curve for this function was found to be
logarithmic in accordance with previous reports (Thorn &
Henney, 1976). A lytic unit n% (LUn) was defined as the
number of effector cells, extrapolated from the dose-response
curve, which were required to achieve n% specific target cell
lysis. LUn 10-6 effector cells was calculated by dividing 106
by the number of lymphocytes corresponding to 1 LUn.
Assayfor CBL proliferation in mixed lymphocyte/tumour
culture
CBL proliferation during coculture with MT-2 infecting cells
was tested either in whole CBL cultures or at an optimal
macrophage:lymphocyte ratio of 1:20, to enhance the
antigen presenting function of macrophages (M0). In this
second case M0 were separated from lymphocytes (Ly) by a
double adherence step, detached by a rubber policeman, and
added to autologous non-adherent cells. fS-IFN (100 or
1000Uml-1) was added as an overnight pretreatment of
CBL or of MT-2 cells, or at the onset of the coculture. CBL
blastogenesis was estimated on days 0, 2, 4, 6 and 8 by
[methyl-3H]-thymidine (2.6-3.1 TBeqmmol -1, Amersham,
UK) incorporation. 3H-thymidine was used at the
concentration of 1 pCi per 2 x 105 cells per well. Samples
were harvested 20h later by microtiter cell harvester
(Titertek 530, Flow Laboratories) and counted in a
scintillation beta-counter (LKB, Bromma, Sweden).
Results
In vitro infection ofCBL with HTLV-I
In vitro infection of CBL with HTLV-I was obtained by
using an optimal CBL: HTLV-I donor-cell ratio (5:1) and
supplementing the culture medium with IL-2, to allow the
survival of lymphocytes. Under these standard conditions,
CBL were susceptible to HTLV-I infection to a variable
I
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extent depending in part on different cord blood donors.
CBL generally responded to challenge with virus-infected
allogeneic cells with a modest initial proliferation that
decreased within 1-2 weeks, and cells passed through a
growth crisis at 3-4 weeks, then the transformed clone(s)
started to expand (data not shown). Addition of /3-IFN to
CBL/MT-2 cocultures (i.e., cotreatment with ,B-IFN) did not
affect the low proliferative response of CBL (data not
shown). Similarly f,-IFN did not depress the proliferation
rate of MT-2 cocultures with K562, HL60 or Molt-4 cells.
Moreover, continuous treatment of MT-2 or K562 cells with
/3-IFN (1000Uml-1 every 2 days) for I week did not inhibit
cell growth (data not shown).
HTLV-I transmission was evaluated by indirect immuno-
fluorescence for the p19 virus core protein in 10 CBL/MT-2
cocultures. A typical experiment, illustrated in Table I,
shows the infection pattern of most CBL cultures: (a) few
cells were positive for the p19 protein until 2-3 weeks of
culture; (b) after 4 weeks this percentage increased in
untreated CBL, but remained very low in IFN-treated CBL;
(c) similar results were obtained both when CBL were
pretreated with IFN before coculturing and when IFN was
added at the onset of the coculture; (d) pretreatment of MT-
2 cells before irradiation and coculture had no effect on the
percentage of pl9+ cells as compared to controls. When
CBL were fractionated and reconstituted to optimal M0:Ly
ratio (1:20) for antigen-presenting function, the presence of
M0 delayed the appearance of pl9+ cells when compared to
Ly alone (Figure 1). However, IFN afforded further
protection against HTLV-I, as evidenced by the significantly
lower number of pl9+ cells in treated M0+Ly cultures as
compared to untreated controls, 5 weeks p.i. (Figure 1).
Positivity for the p19 protein indicates the presence of
virions on the membrane or inside the cells (Aoki et al.,
1984), but does not directly correlate to virus integration in
the host genome. By this test one cannot discriminate
between virus uptake and integration in infected cells.
Hence, dot blot analysis of genomic DNA of CBL,
hybridized with the Sst-I fragment as probe, was performed
to verify whether p19 expression correlated with virus
integration. As shown in Figure 2, the integration of HTLV-
I in 2wk cocultured CBL was quantitatively reduced after
IFN treatment. IFN was effective when used for pretreating
CBL, and also when given as cotreatment. In a 4wk culture,
a clear difference was still observed among IFN-cotreated
CBL in comparison with untreated CBL. On the contrary,
IFN-pretreated CBL showed a spot quantitatively similar to
untreated cells. In one out of 5 whole CBL cocultures,
Weeks
4 5
Figure 1 Time-course of p19 positivity of CBL-derived Ly
(0 O) or M0+Ly ( 0) (1:20) cocultured with lethally
irradiated MT-2 (HTLV-I donor) cells at 5:1 ratio. f,-IFN-
pretreated (A A) or cotreated (M *) (1000 Uml-1)
Ly+M0 cultures were significantly less positive for p19 than
untreated Ly+Mo cultures (P<0.01 at 5 weeks). M0 exerted a
protective effect on Ly during coculture (P<0.01 at 4 weeks and
P<0.05 at 5 weeks comparing Ly to Ly+Mo cultures).
Probability was calculated according to x2 analysis.
however, the number of pl9+ cells was relatively high (20-
25%) 2-3 weeks p.i. and IFN had slight effect, if any, in
decreasing this percentage. Even in this case, however,
provirus integration was greatly impaired by IFN
pretreatment or cotreatment, as indicated by dot blot
analysis performed 2 weeks p.i. (data not shown). This
observation indicates that HTLV-I transmission and
integration can also be independently affected by fl-IFN.
In vitro infection ofhuman tumour cells line
K562, Molt-4 and HL-60 cells were infected by coculturing
with MT-2 cells as for CBL cultures. Viral p19 was assayed
by indirect immunofluorescence 5 days p.i., since HTLV-I
was cytopathic for recipient cells and their viability on day 5
was generally reduced to 40-50%, approaching total cell
death after 10 days.
All 3 cell lines were susceptible to HTLV-I infection and
10-20% cells became pl9+ after 5 days (data not shown).
Pretreatment of the recipient line or cotreatment with fl-IFN
had no effect on HTLV-I infection, with the exception of
one out of two experiments with HL60, in which
Table I Time-course of appearance of p19 positive cells among CBL infected
in vitro with HTLV-I
I wk 2wk 4wk
Samples % pl9 P % pl9 P %pJ9 P
CBL+ MT-2 (controls) 7.62 - 13.07 - 31.47
CBL+MT-2+IFN 100a 6.85 NS 5.81 <0.01 17.93 <0.01
CBL+MT-2+IFN loooa 6.96 NS 3.46 <0.01 9.95 <0.01
(CBL IFN 100)+MT-2b 8.19 NS 4.00 <0.01 16.97 <0.01
(CBL IFN l000)+MT-2b 7.80 NS 5.29 <0.01 12.08 <0.01
CBL+(MT-2 IFN 100)C 6.04 NS ND 26.79 NS
CBL+(MT-2 IFN 1000)C 4.83 NS ND 31.95 NS
Scheme of treatments: aCotreatment of CBL with 100 or 1000 Uml -
P-IFN; b(CBL IFN): overnight pretreatment of CBL with 100 or 1000Uml-1
fl-IFN; C(MT-2 IFN): overnight pretreatment of MT-2 cells (HTLV-I donor
cells) with 100 or 100OUml-1. N.D.=not done. CBL were then cocultured
with irradiated MT-2 cells at 5:1 ratio. Infection was evaluated by indirect
immunofluorescence for the p19 virus core protein. Significance (P) was
calculated by x2 analysis comparing % p19 between CBL+MT-2 and IFN-
treated samples. NS: not significant. Per cent inhibition of p19 positivity 2wks
p.i. in 10 CBL/MT-2 cocultures ranged from 13% to 85%.484 C. D'ONOFRIO et al.
2 wk 4 wk
CBL
CBL + MT-2
CBL + MT-2 + IFN
(CBL + IFN) + MT-2
Figure 2 Dot blots of genomic DNA (3,g/spot) extracted from
CBL cocultured or not with lethally irradiated MT-2 cells and
hybridized with the Sst-I fragment of pMT-2 plasmid. Sample
CBL were cotreated (3rd line) or overnight pretreated (4th line)
with 1000 Uml-1 ,-IFN. Unspecific background of
hybridization was detected by this probe in non-infected CBL.
cotreatment with 1000Uml-1 IFN decreased the percentage
of pl9+ cells from 12.5% (control) to 6.4% (P<0.01).
When virus integration was considered (Figure 3), IFN did
not affect it in K562 cells and had limited influence in HL60
and Molt-4 cells. Overnight or 1 wk pretreatment of MT-2
cells before coculturing did not affect the degree of infection
of recipient cell lines, nor influenced the proliferation rate of
MT-2 cells (data not shown).
Surface markers ofCBL population during infection with
HTLV-I
CBL on day 0 consisted of a mixed population with variable
but low percentages of the subsets identified by the
a
CONTROL
+ MT-2
+ MT-2 + p-IFN
+ (1-IFN) + MT-2
b
MOLT-4 K562 HL60 MT-2
0.5y 1 2y
K562
MOLT-4
MT-2
Figure 3 Panel a: dot blots of genomic DNA (3 pg/spot)
extracted from Molt-4, K562, HL-60 and MT-2 cells, cocultured
(2nd line) or not (controls) with lethally irradiated MT-2 cells
and hybridized with the SstI fragment of pMT-2 plasmid.
Sample cells were cotreated (3rd line) or overnight pretreated
(4th line) with 1000 U ml-' of ,B-IFN. Panel b: dot blot titration
of non-infected K562 or Molt-4 lines and of HTLV-I+MT-2
cells. The non-specific background ofvariable intensity in HTLV-I
free lines was confirmed by Southern blot analysis. By washing
the filters for 30min x SET-0.1% SDS solution at 65°C the
background was reduced, as shown in panel a.
monoclonal antibodies to various surface markers (Table II).
K562 and Molt-4 cells were negative for all the monoclonals
tested. MT-2 cells were 89%. Tac+ and 64% CD4+.
Among infected CBL, on day 4, the number of M0+ and
B+ cells increased, CD8+ cells decreased, and neither
CD4+ nor LGL+ varied. Pretreatment or cotreatment of
infected CBL with f-IFN resulted in a reduced number of
CD8 + and CD4+ cells, whereas pretreatment of MT-2 cells
before coculturing did not affect the phenotypic pattern of
CBL. The relative number of M0, that was highly increased
after coculturing with MT-2 cells, increased much less when
CBL were pre- or cotreated with fl-IFN, thus giving a
percentage closer to non-infected CBL. The percentage of
Tac+ cells was augmented on day 4 among cocultured CBL
as compared to control CBL and was further increased by
IFN treatment. Five weeks p.i. the relative percentages of
CD4+ and Tac+ cells were greatly increased, whereas they
remained low in IFN-treated CBL.
Cell-mediated cytotoxicity offreshly isolated or HTLV-I
infected CBL
Freshly isolated CBL showed low natural cell-mediated
cytotoxicity against K562 target cells and were essentially
non cytotoxic for MT-2 blasts (Table III). However K562
and MT-2 targets were efficiently lysed by fl-IFN pretreated
CBL (Table III). Cell-mediated cytotoxicity of virus-exposed
CBL (hereafter referred to as 'infected CBL') was drastically
reduced as compared with non-infected controls (Table IV).
On day 7, infected CBL were poorly cytotoxic not only for a
typical natural killer target such as K562, but also for the
same infecting and sensitizing allogeneic MT-2 cells, as for
an EBV-transformed tumour cell line (X303, see Table IV
footnote), both the last two lines expressing class I and II
HLA antigens.
IL-2 in the culture medium could boost only the killing
capacity of uninfected CBL against K562 or MT-2 cells,
whereas infected CBL were totally refractory to interleukin
stimulation (Table IV). The poor killing capacity of CBL
against MT-2 cells was not due to the unfavourable ratio of
CBL (responder cells) to MT-2 (sensitizer cells) for eliciting
cytotoxic T lymphocytes (CTL). In fact, CBL infected (and
sensitized) with MT-2 at the optimal infective ratio (5:1) or
at the usual responder/sensitizer cell ratio (40:1) for CTL
generation, were equally unable to kill MT-2 cells (Table
IV).
Pretreatment of CBL with fJ-IFN greatly enhanced the
cytotoxic capacity of infected CBL when tested against K562
or MT-2 cells and this enhancement was detectable up to
4wks of coculture (Table IV).
CBL proliferation in mixed culture with MT-2 tumour cells
Proliferation of mononuclear cells in mixed lymphocyte/
tumour cell culture was evaluated shortly after infection
by 3H-thymidine incorporation in blast cells. Although most
of dividing cells are activated lymphocytes, some dividing
cells can also be monocytes (Van Furth, 1982) triggered by
coculture with MT-2. Thymidine incorporation by normal
CBL was marginal, unless IL-2 was present in the medium.
In this case f1-IFN reduced CBL proliferation by 50%
(data not shown). In the presence of IL-2 in the medium,
infected CBL incorporated 10-15 fold less thymidine than
non-infected controls (day 4-6 p.i.) and f-IFN had no
effect on this low incorporation rate (data not shown).
Thymidine incorporation was measured in CBL cocultured
with MT-2 cells at the optimal M0: Ly ratio for antigen-
presenting function (1:20). Data from a representative
experiment summarized in Table V show that: (a) challenging
with MT-2 cells reduced the IL-2-dependent thymidine
incorporation of M0+Ly much less than that of whole
CBL, or Ly alone; (b) the incorporation rate regained the
control levels when the cells were pretreated or cotreated
with fJ-IFN at 1000Uml -1. In the same experiment, theIN VITRO DEPRESSION OF HTLV-I INFECTION BY f,-IFN 485
Table II Time-course of appearance of phenotype markers of CBL infected in vitro with HTLV-I by coculturing with
irradiated MT-2 (HTLV-I donor) cells at 5:1 ratio
CD4+ CD8+ Tac+
Sample Od 4d 5wk Od 4d 5wk Od 4d 5wk
CBL 14.03 17.16 7.69 11.39 16.92 5.83 5.05 10.41 22.09
CBL+ MT-2 - 16.85 62.37 - 11.06 6.66 - 23.64 54.19
(NS)A (<0.01)A (<0.01)A (NS)A (<0.01)A (0.01)A
CBL+MT-2+IFNa - 7.63 16.51 - 2.09 4.81 - 33.81 23.36
(<0.01)0 (<0.01)0 (<0.01)0 (NS)0 (<0.05)0 (0.01)0
(CBL+IFN)+MT-2b - 5.93 19.24 - 2.13 5.54 - 29.22 25.67
(<0.01)0 (<0.01)0 (<0.01)0 (NS)- (<0.05)0 (<0.01)0
CBL+(MT-2+IFN)C - 18.61 65.00 - 10.63 5.21 - ND ND
(NS). (NS)* (NS). (NS)0
MO+ LGL+ B+
Sample Od 4d 5wk Od 4d 5wk Od 4d Swk
CBL 12.03 3.80 1.34 2.00 1.81 0.00 4.30 3.50 0.00
CBL+MT-2 - 42.00 2.62 - 1.67 0.00 8.43 0.00
(<0.001)A (NS)A (NS)A (NS)A (<0O01)A (NS)A
CBL+MT-2+IFNa - 15.81 1.45 - 1.24 0.00 1.75 0.00
(<0.01)0 (NS)0 (NS)0 (NS)0 (<0.01)0 (NS).
(CBL-IFN)+MT-2b - 21.32 0.91 - 1.37 0.00 1.72 0.00
(<0.01)0 (<0.05)0 (NS)0 (NS) 0 (<0.01) (NS).
CBL+(MT-2+IFN)C - 32.97 1.32 - ND ND - ND ND
(<0.01)0 (NS)-
aCBL+MT-2+IFN: cotreatment with 1000Uml-1 fl-IFN; b(CBL+IFN)+MT-2: overnight pretreatment of CBL with
100OUml-I1-IFN; CCBL+(MT-2+IFN): overnight pretreatment of MT-2 cells with 100OUml-I1B-IFN. The culture
medium was routinely supplemented with 5% IL-2. % positive cells were scored by fluorescence microscopy (indirect
immunofluorescence) or by FACS analyzer (direct immunofluorescence). Data from a representative experiment are given. In
this experiment, MT-2 cells were 64.32% positive for Leu 3a (CD4+) and 89.32% positive for Tac antigens. It has to be
underlined that time of appearance ofCD4+, Tac+, p19+clones is variable among individual CBL donors, ranging from 4 to
8 weeks. Significance was calculated by x2 analysis using CBL as control versus infected CBL (A) or infected CBL as control
versus IFN-treated cocultures (0). ND=not done; NS =not significant.
Table III Natural cytotoxicity (NK) of freshly isolated CBL against 5'Cr-labelled
K562 NK-target and MT-2 (HTLV-I-) target cells
Target: K562 Target: MT-2
Samples Lu1 10-6 CBL P Lu1 10
-6 p
CBL 13.071 - 0.001 -
CBL+IFN (100Uml-1) 28.145 <0.01 4.261 <0.01
CBL+IFN (1000 Uml-1) 27.758 <0.01 4.910 <0.01
Sample CBL were pretreated overnight with 100 or 1000Uml ,B-IFN.
Cytotoxicity is expressed as lytic units (Lu1o 10-6 CBL) calculated on the basis
of the geometric mean +s.e. Probability (P) was calculated according to
regression test analysis comparing NK activity between control CBL and IFN-
treated CBL.
appearance of p19 positive cells in cocultured CBL was
delayed and M0 showed a protective effect on Ly infection
(Figure 1). ,B-IFN further reduced the percentage of pl9+
cells of this culture (Figure 1).
Discussion
Human peripheral, bone marrow and cord blood lympho-
cytes can be transformed efficiently in vitro by co-
cultivation with lethally irradiated allogeneic (Miyoshi
et al., 1981; Merl et al., 1984; Markham et al., 1984) or
autologous (Akagi et al., 1985) HTLV-I positive cell lines.
Immature cells (cord blood or bone marrow lymphocytes)
are easily infected in vitro in comparison with the peripheral
blood lymphocytes of adult donors (Graziani et al., 1987).
This might also occur in vivo, since bone marrow
lymphocytes may represent a more permissive target for
HTLV-I in adults, as is the case of instances of mother to
foetus transmission.
To test the effect of fl-IFN on HTLV-I transmission in
vitro, experiments were carried out with highly permissive
but potentially immunocompetent cells, which are easily
available in large quantity. Under our test conditions, CBL
were infected in vitro by coculturing with the lethally
irradiated allogeneic MT-2 (HTLV-I+) cell line. Among
IFN-treated CBL, the percentage of p19+ cells was
generally reduced up to 4 weeks p.i. in comparison with non-
treated controls. This decrease possibly reflects an IFN-
mediated depression of either transmission and integration of
HTLV-I in the host genome. In fact, a parallel study on viral
DNA extracted with host cell DNA and identified by the486 C. D'ONOFRIO et al.
Table IV Cell-mediated cytotoxicity of CBL cocultured with HTLV-I+ MT-2 cells. Cytotoxicity was tested by
5"Cr-relase assay against a typical natural killer target (K562) or against HTLV-I producer MT-2 cells
day0 JKwk 2wk 4wk
Effector cells Target cells Lu1o O-6 Luo10 6 P Lu1o-6 P 10106 P
CBL K562 17.24 1443.57 ND ND
CBL+MT-2 K562 - 2.61 <0.01A 8.48 - 0.13 -
(CBL+IFN 1000)+MT-2 K562 - 37.57 <0.010 28.75 <0.01 9.74 <0.010
CBL MT-2 2.72 417.34 ND ND
CBL+ MT-2 MT-2 - 0.02 <0.01A 24.72 - 0.05 -
(CBL+IFN 1000)+MT-2 MT-2 12.27 <0.010 45.86 <0.010 9.26 <0.010
CBL were infected by coculturing with lethally irradiated MT-2 cells at 5: 1 ratio, in IL-2 supplemented
medium. Samples with CBL: MT-2 infecting ratio of 40: 1, according to standard conditions to generate CTL in
vitro, tested 1 wk p.i., resulted in similar low cytotoxic response of CBL (target MT-2, Lul010-6 CBL=0.0004),
in spite of IL-2 supply in the culture medium. In the same experiment, when CBL were primed on day 0 with an
EBV-immortalized cell line (X303) expressing both class I and II HLA antigens, the CTL response on day 7 was
greatly increased at priming ratio of 40:1 (Lulo 10-6=8.42), in comparison with 5:1 ratio (Lulo 10-6=0.009). /3-
IFN was given as overnight pretreatment of CBL (1000Uml-1) before coculturing. Probability (P) was
calculated according to regression test analysis comparing CBL versus infected CBL (A) or infected IFN-treated
CBL versus untreated cells (0). ND=not done.
Table V Antigen presenting function of macrophages (M0) and lymphocyte (Ly) blastogenesis during the 1st
week after coculture of CBL with HTLV-I producer MT-2 cells
Days 0 2 4 6 8
Experiment:
Ly 1,484+119 7,428+ 180 25,272+1,711 44,697+3,186 21,523+ 979
Ly+M0 1,833+ 74 46,734+ 1,941 133,595+6,444 73,795+8,241 13,063+2,415
Ly+Mo+IFN 5,390+450 22,484+ 900 61,430+7,664 106,854+5,590 ND
Ly+MT-2 946+ 97 5,018+ 127 14,563+1,540 13,337+1,150 24,444+3,591
Ly+M0+MT-2 5,329+542 33,541 + 1,273 102,897+ 811 54,229+ 349 10,023+ 544
Ly+M0+MT-2+IFNa 6,694+161 41,828+3,074 130,648+9,429 68,606+3,168 41,089+4,281
(Ly+M0+IFN)+MT-2b 1,422+ 58 14,234+1,314 107,224+6,848 124,154+(9,734) 20,696+2,628
Cord blood mononuclear cells were separated by adherence steps and reconstituted at M0: Ly ratio of 1:20.
Cells were then infected with HTLV-I by coculturing with irradiated MT-2 virus donor cells (5:1 ratio). 5% IL-2
was added to the culture medium. Recipient cells were cotreated a or pretreated b with 100OUml- fl-IFN. 3H-
methyl thymidine (1 pCi/well) was added 20h before harvesting. Data are given as c.p.m. +s.e.m. for
quadruplicate samples. ND =not done.
HTLV-I probe (dot blots) showed a reduction of virus
integration in IFN-treated CBL at 2 weeks p.i. At 4 weeks
p.i., provirus integrated DNA was still low in IFN-cotreated
CBL cultures, whereas in IFN-pretreated CBL it became
closer to untreated CBL. It is reasonable to suggest that,
after 4 weeks, cells which had effectively integrated HTLV-I
provirus expanded independently of early IFN treatment,
although not all cells expressed p19 antigen (c.f. Table I). On
the other hand, HTLV-I integration was also clearly reduced
by IFN in cases in which the percentage of p19+ CBL was
only slightly affected (data not shown).
These data suggest that transmission and integration of
HTLV-I might be independently affected by fl-IFN. In a
murine sarcoma virus model, IFN was found to delay viral
DNA synthesis and its transport to the nucleus and, most of
all, to greatly reduce viral DNA integration by inhibiting the
accumulation of supercoiled viral DNA (a precursor to
integrated provirus) in the nucleus (Huleihel & Aboud,
1983). fl-IFN was also shown to inhibit stabilisation and/or
integration of exogenous oncogene sequences in the recipient
cells, with an apparent effect on gene expression that
reduced stable transformation by oncogenes (Perucho &
Esteban, 1985). What is relevant to our experiments is that
the effect of fl-IFN on the transmission and integration of
HTLV-I provirus was evident most of all in CBL, which are
immunocompetent cells and among which CD4+ lymphocytes
represent the preferential target for HTLV-1, and much less
when human tumour lines were infected. In this case the
percentage of p19 + cells was unchanged and dot blots
revealed similar quantitative spots for both treated and
untreated cells, with a borderline effect only in IFN-
pretreated Molt 4 and HL-60 cells. Lack of this effect of
IFN on the tested human tumour cell lines is not
attributable to the absence of IFN-IFN/receptor interactions
in these cells. In fact, IFN could efficiently activate the
enzyme (2'-5')-A.-synthetase (Minks et al., 1979) in these
cells up to normal levels of sensitive targets (data not
shown). The enzyme was inducible in extremely high
amounts in HL-60 cells, that were also the most responsive
line to the antiviral effect of fl-IFN (Table II and Figure 3).
Hence, it seems that fl-IFN can affect transmission and
integration of HTLV-I provirus in specific target cells. This
raises the question whether products of other cellular genes
cooperates with IFN to counteract HTLV-I infection.
In vitro infection of CBL with HTLV-I was followed by
remarkable depression of cell-mediated immune functions,
partially reversed by P-IFN. This boosting is likely to
contribute to the inhibition of HTLV-I infection in IFN-
treated CBL. In fact, IFN had no effect when MT-2
infecting cells were treated before coculturing with CBL, nor
when non-immunocompetent human tumour lines were used
as recipient cells.
The capacity of fl-IFN to control HTLV-I infection via
the immune response was suggested in particular during the
early days after in vitro infection. In infected CBL the
relative percentage of monocyte/macrophages increasedIN VITRO DEPRESSION OF HTLV-I INFECTION BY f3-IFN 487
many fold as compared to controls and the number of Tac+
lymphocytes was doubled. After IFN treatment, the
percentage of monocytes, CD4+ and CD8+ lymphocytes
was reduced and that of Tac+ lymphocytes was increased.
Five weeks later, among infected CBL, CD4+ lymphocytes
were predominant and many cells expressed IL-2 receptors,
according to the most frequent phenotype of HTLV-I
infected CBL (Hattori et al., 1981; Waldmann et al., 1984).
On the contrary, among IFN-treated CBL only few cells
were CD4+ lymphocytes and expressed Tac receptors,
exhibiting phenotypic markers closer to normal uninfected
CBL.
IFN potentiated natural immunity by enhancing the NK
activity of non-infected CBL, that normally show less killing
capacity as compared to PBL (Nair et al., 1985). Moreover,
the poor killing capacity of infected CBL against K562
target cells was still enhanced by IFN during the culture
period. This effect of IFN should be underlined considering
that a decline of natural killer activity of lymphocytes was
found in HTLV-I infected patients (De Vecchis et al., 1985)
and that large granular lymphocytes (LGL) with NK activity
have recently been shown to afford T-cell protection from
infection of PBL by HTLV-I (Ruscetti et al., 1986; Macchi
et al., 1987). The fact that few CBL were positive for Leu7
phenotype marker of LGL (Table III) does not rule out their
role against HTLV-I infection, since the phenotype of LGL
differs in CBL compared with PBL and may also be Leu7
(Vitiello et al., 1984).
A more efficient antisensitizer cytotoxic response might
also be relevant in the very early phase of infection to reduce
spreading of infected cells. HTLV-I infection of CBL causes
a severe reduction of their cytotoxic capacity, independent of
the infecting ratio (CBL: MT-2 =5:1 or 40:1). Under these
conditions, the ability of f-IFN to boost the whole killing
capacity of CBL (against both K562 and MT-2 cells) during
long-term culture could conceivably play a role in
counteracting in vitro transmission of HTLV-I. One single
treatment with 1000Uml-1 of IFN just before infection was
highly effective. The possibility that IFN would prevent
HTLV-I infection via suppressive effects on target cell
proliferation appears to be ruled out by the fact that
coculture of CBL with HTLV-I producer MT-2 cells reduced
the 3H-thymidine incorporation of whole CBL to very low
levels that were not further affected by IFN treatment (data
not shown). In these conditions, however, the suppressive
role of M0 might be prevalent (Holt et al., 1981; Veit, 1982).
By repeating the test at the optimal M0:Ly ratio of 1:20,.it
was found that blastogenesis was much less reduced during
coculturing, compared with the level in whole CBL cultures
and fl-IFN could restore proliferation levels comparable to
those of non-infected controls.
In this MT-2/CBL allogeneic system, the level of 3H-
thymidine incorporation in mononuclear blasts is a result of
activation of the immune response. M0 are supposed to
contribute in part to the amount of 3H-thymidine
incorporation, since their proportion is highly increased
within 4 days p.i., as shown by determination of the M3
phenotype. In addition, the optimal M0/Ly ratio for antigen-
presentation resulted in highly effective protection against
HTLV-I transmission, since the relative number of pl9+
cells remained low up to 5 weeks of culture and fl-IFN
further increased this protective effect. Hence, efficient
macrophage function together with high killing capacity of
effector cells are likely to protect against HTLV-I infection
in vitro. The boosting effect of IFN was demonstrated on the
overall cytotoxic capacity of CBL and on their proliferation
in response to infecting allogeneic cells. Thus, JJ-IFN may
reduce the severe depression of immune function that follows
HTLV-I infection, in addition to direct cell-type specific
protection from integration of HTLV-I provirus. These
combined effects of fl-IFN can afford a good protection
from HTLV-I infection in vitro and suggest a role for fJ-IFN
in the prophylaxis of HTLV-I infection in endemic areas
with a high incidicidence of serum-positive subjects.
Moreover, the present study would encourage extension of
immunomodulating approaches for the management of
retroviral infections in human pathology.
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